Combination of a BTK inhibitor and an MDM2 inhibitor for cancer treatment

Therapeutic methods and pharmaceutical compositions for treating a cancer, including a B cell hematological malignancy selected from the group consisting of chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), non-Hodgkin's lymphoma (NHL), diffuse large B cell lymphoma (DLBCL),...

Full description

Saved in:
Bibliographic Details
Main Author ROTHBAUM, WAYNE
Format Patent
LanguageChinese
English
Published 01.08.2021
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Therapeutic methods and pharmaceutical compositions for treating a cancer, including a B cell hematological malignancy selected from the group consisting of chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), non-Hodgkin's lymphoma (NHL), diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), Hodgkin's lymphoma, B cell acute lymphoblastic leukemia (B-ALL), Burkitt's lymphoma, and Waldenstrom's macroglobulinemia (WM).
Bibliography:Application Number: TW20209139607